Clinical Trials Sponsored by Huma

Total 3248 results

Hama University

Recruiting

Comparison of Two Types of Lingual Fixed Retainer Fabricated (malocclusion)

Malocclusion, Angle's Class

Syrian Arab Republic
Hama University

Recruiting

Treatment of Skeletal Class II Malocclusion With Modified Twin-Block Appliance With Clear Plates

Malocclusion, Angle Class II

Syrian Arab Republic
Hama University

Recruiting

Evaluating the Efficacy of Micro-Osteoperforations Technique on the Orthodontic Tooth Movement Acceleration in Moderate Mandibular Anterior Crowding Cases Treated With Clear Aligners

Crowding of Anterior Mandibular Teeth

Syrian Arab Republic
Hama University

Completed

The Efficacy of Tow Mechanics for Total-maxillary-arch-distalization

Malocclusion | Class II Division 1 Malocclusion

Syrian Arab Republic
Hama University

Completed

Use of Anatomical Landmark in Locate Occlusal Plane.

Dentulous

Syrian Arab Republic
Hama University

Recruiting

Evaluating the Effect of Injectable Platelet-rich Fibrin on Accelerating Orthodontic Tooth Movement

Tooth Mobility | Injectable Platelet-rich Fibrin

Syrian Arab Republic
Hama University

Completed

A Technique for Border Molding in Complete Dentures Using Light-Cured

Edentulous Mouth

Syrian Arab Republic
Hama University

Recruiting

Treatment of Mild Class II Malocclusion in Adult Patients With Clear Aligners Versus Fixed Multibracket Therapy (malocclusion)

Malocclusion | Class II Malocclusion

Syrian Arab Republic
Center for Human Reproduction
Foundation for Human Reproduction

Enrolling by invitation

Effect of Influenza Vaccination on IVF Outcomes - IVF (IVF-FluVac)

Infertility

United States
Puma Biotechnology, Inc.

Recruiting

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer (ALISCA-Lung1)

Small Cell Lung Cancer

United States
LUMA Vision Ltd.

Not yet recruiting

Feasibility Study on the VERAFEYE System (LUMINIzE)

Atrial Fibrillation | Atrial Septal Defect | Left Atrial Appendage Closure | Atrial Arrhythmia
Puma Biotechnology, Inc.

Completed

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)

Breast Cancer

United States, Spain, Korea, Republic of, China, United Kingdom, Canada, France, Australia, Denmark, Switzerland, Japan, Malaysia, Italy, Singapore, Taiwan, Belgium, Croatia, Czechia, Romania, Germany, Bahamas, Brazil, Bulgaria, Colombia and more
Puma Biotechnology, Inc.

Completed

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Advanced Malignant Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer

Korea, Republic of, Taiwan, Hong Kong, United States, Japan, Croatia, United Kingdom, Hungary, Australia, Canada, Serbia, Singapore, South Africa, Poland, Spain, Russian Federation, Romania, Austria, Belgium, Bulgaria, Czechia, Fr... and more
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Advanced Breast Cancer

United States, Switzerland, China, France
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 Administered to Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

Hepatic Insufficiency

Russian Federation
Center for Human Reproduction
Foundation for Human Reproduction

Unknown

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes (DE-FluVac)

Infertility | Recurrent Miscarriage

United States
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
LUMA Vision Ltd.

Not yet recruiting

Registry on Luma Vision's VERAFEYE System (ENLIgHT) (ENLIgHT)

Atrial Fibrillation | Left Atrial Appendage Closure | Atrial Arrhythmia
Puma Biotechnology, Inc.

Completed

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

HER2 Amplified Breast Cancer

Portugal
Puma Biotechnology, Inc.

Completed

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Early Stage HER2+ Breast Cancer

Spain, United States, France, Australia, Germany, Austria, Canada
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
Puma Biotechnology, Inc.

Terminated

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Metastatic Cervical Cancer | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Spain, Israel, United States, Serbia, France, Ireland, Italy
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT)

Breast Cancer

Spain, China, United States, Australia, Hong Kong, Malaysia, Korea, Republic of, Singapore, Belgium, Japan, India, France, Hungary, Romania, Italy, Bulgaria, Germany, Serbia, United Kingdom, South Africa, Canada, Israel, Taiwan, Switz... and more
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Neoplasms | Breast Neoplasms

United States, Belgium, India, China, Russian Federation, Mexico, France
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Breast Cancer | Advanced Malignant Solid Tumors

United States, Taiwan, United Kingdom, Hong Kong, Belgium, France, Spain, China, Netherlands, Poland, Sweden
Puma Biotechnology, Inc.

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer

United States, France
Puma Biotechnology, Inc.

Completed

Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

Healthy Subjects

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

Healthy

United States
Puma Biotechnology, Inc.

Completed

HKI-272 Ketoconazole Drug Interaction Study

Healthy
Puma Biotechnology, Inc.

Completed

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Breast Cancer

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects

Healthy
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Puma Biotechnology, Inc.

Completed

Study Evaluating Safety And Tolerability, Solid Tumor

Advanced Malignant Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Breast Cancer

Spain, United Kingdom, France, United States, Denmark, Hong Kong
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Neoplasms | Malignant Carcinoma

United States, France
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 in Tumors

Breast Neoplasms

United States
Puma Biotechnology, Inc.

Completed

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Breast Cancer

United States, Spain, China, Hungary, Singapore, Australia, Russian Federation, Hong Kong, Brazil, Croatia, Korea, Republic of
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Advanced Malignant Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States, France, Hungary, Poland, Spain
Puma Biotechnology, Inc.

Completed

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Completed

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Withdrawn

Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

Healthy
Puma Biotechnology, Inc.

Completed

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

Healthy Subjects

United States
Puma Biotechnology, Inc.

Completed

Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

Healthy

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Healthy Subjects

United States
Center for Human Reproduction

Recruiting

Study of PRP in Women With Evidence of Diminished Ovarian Reserve (PRP4AGE)

Diminished Ovarian Reserve | Ovarian Failure

United States

Clinical Trials Sponsored by Huma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations